Safety, Tolerability, and Efficacy of CP-PCA07 in Combination With Enzalutamide in Patients With Castration-Resistant Prostate Cancer

NCT07683013 · clinicaltrials.gov ↗

PHASE1

Phase

NOT_YET_RECRUITING

Status

18

Enrollment

INDUSTRY

Sponsor class

Conditions

Castration-Resistant Prostate Cancer (CRPC)

Interventions

DRUG: CP-PCA07
DRUG: Enzalutamide 40 mg capsule

Sponsor

Hyundai Bioscience Co., Ltd.